Decoy Biosystems News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Intec Closes Merger with Decoy Biosystems USA - English Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus News provided by Share this article Share this article NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company," and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ("Decoy") and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus T...

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: PRA Health Sciences, Inc. (NASDAQ:...

Share this article Share this article NEW YORK, May 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: PRA Health Sciences, Inc. (NASDAQ: PRAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ICON plc. Under the terms of the transaction, PRA Health shareholders will receive $80.00 in cash and 0.4125 shares of ICON stock for each PRA Health share that they own. WSFS Financial Corporation (NASDAQ: WSFS)  concerning potential violation...

Intec Pharma Ltd. (NASDAQ: NTEC)  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intec Pharma Ltd. (NASDAQ: NTEC) in connection with the proposed acquisition of the company by Decoy Biosystems, Inc. ("Decoy"). Upon consummation of the transaction, NTEC's shareholders will own approximately 25% of the combined entity, with Decoy shareholders owning approximately 75%. If you own NTEC shares and wish to discuss this investigation or your rights, please call us or visit our website: https://weisslawllp.com/ntec/  Ru...

Health your username 6 days ago A stockholder is suing Intec Pharma Ltd., Intec’s board of directors, and related entities over alleged violations of the Securities Exchange Act, per a Friday complaint filed in the District of Delaware regarding a proposed merger. Plaintiff Craig Davidson is an owner of common stock of Intec, a biopharmaceutical company developing drug products based on its Accordion Pill platform that seeks to “improve the efficacy and safety” of drug products. On March 15, Intec’s board of directors executed a merger agreement with Intec Parent, Inc., Dillion Merge...